Dr. Fakih on Angiogenesis Versus EGFR Inhibitors in CRC

Partner | Cancer Centers | <b>City of Hope</b>

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses anti-angiogenesis versus anti-EGFR therapy in patients who have RAS wild-type colorectal cancer.

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses anti-angiogenesis versus anti-EGFR therapy in patients who have RAS wild-type colorectal cancer.

Fakih says it is important for researchers to figure out which therapy is more beneficial for patients who have RAS wild-type colorectal cancer in the first-line setting. There are hints that anti-EGFR therapy is effective in the first-line setting based on the FIRE-3 data, Fakih says, but it is important to see the results of C80405. Especially since the FIRE-3 data shows a lack of improvement in patient’s progression-free survival.

​